Live Breaking News & Updates on 023 Ocgn Us67577c1053

Stay updated with breaking news from 023 ocgn us67577c1053. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

U.S. Food & Drug Administration grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3MALVERN, Pa., April 27, 2023 . | April 27, 2023 ....

United States , Shankar Musunuri , Us Food Drug Administration , Exchange Commission , Ocugen Inc , Nuclear Hormone Receptors Nhrs , Drug Administration , Orphan Drug Designation , Retinitis Pigmentosa , Orphan Receptor , Nuclear Hormone Receptors , Private Securities Litigation Reform Act , Nc Stock Exchange , Press Release , 023 Ocgn Us67577c1053 ,

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosisMALVERN, Pa., April 11, 2023 . | April 11, 2023 ....

Shankar Musunuri , Tarun Upadhyay , Neenab Haider , Retina Foundation Of The , Head Of Clinical Development , Ocugen Inc , Head Of Research , Exchange Commission , Analyst Event , Chief Scientific Officer , Clinical Development , Medical Affairs , Scientific Director , Retina Foundation , Conference Call , Private Securities Litigation Reform Act , Nc Stock Exchange , Press Release , 023 Ocgn Us67577c1053 ,